Bain Capital Specialty (NYSE:BCSF) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.50 by 6 percent. This is a 3.64 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $72.54 million which beat the analyst consensus estimate of $69.75 million by 4.00 percent. This is a 0.21 percent increase over sales of $72.39 million the same period last year.
![share_log](https://pubimg.futunn.com/2022050900000169e93b3da250f.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
- Headlines
- Bain Capital Specialty Q3 EPS $0.53 Beats $0.50 Estimate, Sales $72.54M Beat $69.75M Estimate
Bain Capital Specialty Q3 EPS $0.53 Beats $0.50 Estimate, Sales $72.54M Beat $69.75M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Log In for the Full List
Latest
19:02
Insiders: The news about Xiaohongshu bringing in state-owned Shareholders is false.
19:02
Lacking catalysts for momentum, Bitcoin continues to hover below the $0.1 million mark.
Bitcoin+0.08%
19:01
INNOCARE: The BCL2 inhibitor ICP-248 combined with the obinutuzumab treatment has received approval from the CDE to conduct a registered Phase III clinical trial for first-line CLL/SLL.
INNOCARE-0.61%
Investment Course
![](https://courseimg.futunn.com/1713951982904.png)
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha